NeuroPace Inc [NPCE] stock prices are up 38.09% to $12.98 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NPCE shares have gain 28.13% over the last week, with a monthly amount glided 21.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NeuroPace Inc [NASDAQ: NPCE] stock has seen the most recent analyst activity on May 28, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $18. Previously, UBS started tracking the stock with Buy rating on January 21, 2025, and set its price target to $17. On March 14, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $20 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $22 on January 30, 2024. Cantor Fitzgerald initiated its recommendation with an Overweight and recommended $11 as its price target on November 10, 2023. Morgan Stanley upgraded its rating to Equal-Weight for this stock on August 24, 2023, and upped its price target to $6. In a note dated February 22, 2023, Lake Street initiated a Buy rating and provided a target price of $10 on this stock.
The stock price of NeuroPace Inc [NPCE] has been fluctuating between $6.27 and $18.98 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. NeuroPace Inc [NASDAQ: NPCE] shares were valued at $12.98 at the most recent close of the market. An investor can expect a potential return of 34.82% based on the average NPCE price forecast.
Analyzing the NPCE fundamentals
The NeuroPace Inc [NASDAQ:NPCE] reported sales of 94.86M for trailing twelve months, representing a surge of 29.89%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.19%, Pretax Profit Margin comes in at -0.22%, and Net Profit Margin reading is -0.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -1.17 and Total Capital is -0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.23 points at the first support level, and at 9.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.27, and for the 2nd resistance point, it is at 15.56.
Ratios To Look Out For
It’s worth pointing out that NeuroPace Inc [NASDAQ:NPCE]’s Current Ratio is 4.86. Also, the Quick Ratio is 3.94, while the Cash Ratio stands at 1.05. Considering the valuation of this stock, the price to sales ratio is 4.53, the price to book ratio is 23.33.
Transactions by insiders
Recent insider trading involved ORBIMED ADVISORS LLC, 10% Owner, that happened on May 14 ’25 when 0.17 million shares were sold. CHIEF MEDICAL OFFICER, Morrell Martha completed a deal on Feb 21 ’25 to sell 78334.0 shares. Meanwhile, 10% Owner KCK LTD. sold 5.27 million shares on Feb 20 ’25.
